This content is from: Premium
Tourbillon’s Big Short Pays Off in Q3
Jason Karp’s firm posted a strong third quarter in part due to the collapsing price of a struggling biotech company.
Shares of biotechnology firm MannKind Corp., which specializes in therapeutic products for diabetes and has been in free fall lately, plummeted another 8 percent or so on Friday, to close at a new low of about $0.50 per share. This is bad news for MannKind stockholders but is particularly good news
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.